AdAPT-001

AXP000040.1 · Oncolytic virus

Platform
adenovirus (Ad5, TGF-beta trap-armed)
Originator
EpicentRx
Sponsor
EpicentRx

Names

NameTypeSource
AdAPT-001preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (AdAPT-001)
Replication
conditionally replicating
Modifications
armed with a TGF-beta trap
Transgenes
TGF-beta trap
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C179574

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04673942A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid TumorsActive not recruitingPhase 22021-03-292026-12-01140Cancer; Chondrosarcoma; Neoplasms; Sarcoma; Sarcoma,Soft Tissue; Solid Tumor, Adult

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 38146006BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.Cancer gene therapy2024name in title: AdAPT-001
PMID 38886116Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing.Journal for immunotherapy of cancer2024cited by trial NCT04673942
PMID 39461878TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance.Journal for immunotherapy of cancer2024cited by trial NCT04673942
PMID 37008834Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient.Case reports in oncology2023name in title: AdAPT-001
PMID 35950603BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.Future oncology (London, England)2022cited by trial NCT04673942

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 37382299Data Management 101 for drug developers: A peek behind the curtain.Clinical and translational science2023name in abstract: AdAPT-001
PMID 35968324AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes in vivo resistance to PD-L1-immunotherapy.American journal of cancer research2022name in title: AdAPT-001
PMID 34765319Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta.American journal of cancer research2021name in title: AdAPT-001

Notes

Oncolytic adenovirus carrying a TGF-beta trap transgene. Phase I/II BETA PRIME, NCT04673942, intratumoral, alone and with a checkpoint inhibitor.

How to cite

AdAPT-001 (AXP000040.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000040.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.